TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06452550

Intervention type: DIAGNOSTIC_TEST
Intervention: Logistic regression (LR) prediction models
Description: Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Logistic regression (LR) prediction models
Description: Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
Study: NCT04931615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)
Description: Wound sealant
Study: NCT04647435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal®
Description: APSCTC placebo + Toragesic® placebo + Tramal®
Study: NCT06728033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supra-inguinal fascia iliaca compartment block
Description: Supra-inguinal fascia iliaca compartment block with 40 ml of 0.25% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: intravenous tramadol at a dose of 2 mg/kg
Study: NCT06728657

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HFRT targeted to the primary lesion and positive lymph nodes
Description: Hypofractionated radiotherapy (HFRT) targeted to the primary lesion and positive lymph nodes (4Gy × 6 fractions)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR targeted to the primary lesion and positive lymph nodes
Description: Irradiation targeted to the primary lesion and positive lymph nodes (6 Gy/1 fraction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status. The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once daily, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status. The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once daily, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 total/subtotal gastrectomy with D2 lymphadenectomy
Description: For resectable participants, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 total/subtotal gastrectomy with D2 lymphadenectomy
Description: For resectable participants, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion.
Study: NCT06727591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split Bone Block Technique
Description: An intraoral crestal incision with/out vertical arms was performed on alveolar ridge using blade no.15. After flap reflection, patroning the defect to help guide the area to be grafted from the donor site. At the chin area (donor site) unicortical cuts will be made at least 5 mm inferior to root tips, 5 mm superior to inferior border of mandible and 5 mm away from the mental foramen. The graft was luxated and split into two bone shells each 1 \~ 2 mm in thickness using disc. The bone shells and the donor site were scrapped for autogenous graft particles. Decortication of the recipient site. The graft was stabilised into the recipient site using two or more self tapping titanium screws placed midway corono-apical in the bone shell following the ridge contour. The autogenous particles were packed into the space between the split bone block and the ridge. Collagen sponge was used to cover the donor site. After 4 months the site was approached for implant placement using crestal incision
Study: NCT06727916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBT-I
Description: Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care. Healthcare provider provided BBT-I to the patients.
Study: NCT04931615

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no ARTISS
Description: Wound closed without sealant
Study: NCT06727916

Intervention type: OTHER
Group type: OTHER
Intervention: Non BBT-I
Description: Patients in the control group will receive standard care.
Study: NCT06728800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT 2.0
Description: FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traﬃc Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The ﬁnal product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.
Study: NCT05666973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Mesh Hernioplasty
Description: * Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Mesh Hernioplasty
Description: * Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture
Study: NCT06728800

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-and-referral
Description: Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
Study: NCT05598567

Intervention type: OTHER
Intervention: target controlled infusion - total intravenous general anesthesia
Description: Both interventions are subtypes of general anesthesia.

Intervention type: OTHER
Intervention: sevoflurane based balanced general anesthesia
Description: Both interventions are subtypes of general anesthesia.
Study: NCT05849857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
Study: NCT05733338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Hypoxia
Description: The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent Hypoxia
Description: The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
Study: NCT06535659

Intervention type: DEVICE
Intervention: VitaFlow Liberty™ Transcatheter Aortic Valve System
Description: Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.~Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.
Study: NCT06433947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-6602
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-6602
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-6602
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
Study: NCT05498987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar 448 kilohertz radiofrequency stimulation
Description: 448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant Achilles Tendon
Study: NCT05859516

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
Study: NCT06317012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate
Description: Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software.
Study: NCT04472702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cRFA
Description: cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cRFA
Description: cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
Study: NCT05608057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C mesotherapy
Description: Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser
Description: Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
Study: NCT05470647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-4 receptor responders 1
Description: Interleukin-4 receptor was injected subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-4 receptor responders 2
Description: Interleukin-4 receptor was injected subcutaneously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was injected subcutaneously.
Study: NCT04963790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored COVID-19 vaccine messages
Description: Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other health messages
Description: Other health messages unrelated to COVID-19 will be sent to participants in the control arm
Study: NCT05869890

Intervention type: DEVICE
Group type: OTHER
Intervention: MOSES laser system
Description: A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,

Intervention type: DEVICE
Group type: OTHER
Intervention: MOSES laser system
Description: A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,

Intervention type: DEVICE
Group type: OTHER
Intervention: MOSES laser system
Description: A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Study: NCT05737511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Oxalate
Description: The treatment as usual can include first-line, second-line and third-line recommendations
Study: NCT05741333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo+ Tympanostomy Tube Device (Solo+ TTD)
Description: The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.
Study: NCT04905992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline at 6%
Description: Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline at 6%
Description: Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (oscillating positive expiratory pressure therapy)
Description: Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance techniques (oscillating positive expiratory pressure therapy)
Description: Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
Study: NCT05246995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI325+Sintilimab
Description: IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
Study: NCT05008523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioids and Police Safety Occupational Risk Reduction Training (OPS)
Description: Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opioids and Police Safety Occupational Risk Reduction Training (COVID)
Description: Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
Study: NCT06519058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-myofascial stretching
Description: self-myofascial stretching exercise

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy treatment, including exercises
Study: NCT05473559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block with Ipack block or selective tibial nerve block
Description: Ultrasound guided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block with Ipack block or selective tibial nerve block
Description: Ultrasound guided
Study: NCT05894902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SM-001
Description: The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SM-001
Description: The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SM-001
Description: The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
Study: NCT05154877

Intervention type: DEVICE
Intervention: OMNI PET/CT Scan
Description: The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.

Intervention type: DEVICE
Intervention: OMNI PET/CT Scan
Description: The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.